HMBOX1 knockout polyclonal HeLa cells constitute a CRISPR/Cas9-mediated polyclonal knockout population designed for functional studies of the HMBOX1 gene. This product comprises a heterogeneous mixture of HeLa cells carrying targeted disruptions, providing a loss-of-function model that captures the range of editing outcomes without clonal isolation. The polyclonal format is advantageous for experiments requiring population-averaged responses, such as autophagy flux measurements, telomerase activity assays, or pooled chemical screens, where clonal variation can confound results.
The host HeLa cell line is an immortalized epithelial line derived from a cervical adenocarcinoma of Henrietta Lacks in 1951. It is HPV-18-positive, with viral E6 and E7 oncoproteins inactivating p53 and retinoblastoma protein (Rb), respectively, leading to deregulated cell cycle progression and high proliferation. HeLa cells are a mainstay of cancer research, offering robust growth, efficient transfection, and a well-characterized signaling background that facilitates investigation of HPV-driven oncogenesis and associated cellular processes.
HMBOX1 (Homeobox-containing protein 1) is a transcription factor that suppresses autophagy and telomerase activity while promoting apoptosis. It is regulated by p53, tumor necrosis factor alpha (TNF-??), and interferon gamma (IFN-??). At the molecular level, HMBOX1 transcriptionally represses the autophagy genes ATG5 and BECN1, inhibiting autophagosome formation. Simultaneously, it promotes apoptosis by upregulating BAX and downregulating BCL-2, thus facilitating apoptosis. HMBOX1 directly interacts with the shelterin component TRF2 and its binding partner RAP1 to repress TERT expression and telomerase activity. Furthermore, HMBOX1 modulates NF-??B signaling through physical interaction with the p65 subunit and importin alpha, influencing the transcription of pro-inflammatory cytokines IL-6 and IL-8.
In the HeLa context, where p53 is constitutively inactivated by HPV E6, HMBOX1 regulation is primarily driven by inflammatory cytokines rather than p53. Knockout of HMBOX1 therefore results in robust derepression of autophagy and telomerase, accompanied by diminished apoptosis, mirroring the loss of its inhibitory functions. This cellular background illuminates p53-independent pathways governing autophagy?Capoptosis crosstalk and highlights cytokine-mediated control of HMBOX1. Moreover, elevated telomerase activity counteracts telomere shortening, potentially impacting genomic stability over prolonged culture. The polyclonal knockout model thus allows dissection of HMBOX1??s network functions in a cancer-relevant setting.
These knockout cells are suited for a broad array of research applications, including cancer cell biology, autophagy signaling, telomere biology, apoptosis, and drug resistance. Typical assays include western blotting for LC3, BAX, and BCL-2; TRAP assays for telomerase activity; Annexin V/PI flow cytometry; and immunofluorescence microscopy to quantify LC3 puncta. Transcriptional changes in ATG5, BECN1, and TERT are measured by RT-qPCR, while ChIP-qPCR can assess HMBOX1 occupancy at telomeres. NF-??B luciferase reporter assays and high-throughput screening for autophagy or apoptosis modulators are also feasible. For technical information or custom gene-editing inquiries, please contact Ascent Research.
